Gilead and Kite Pipeline.

Active and planned clinical trials

The safety and efficacy of these investigational agents and/or uses have not been established. There is no guarantee that they will become commercially available.

Our scientific focus areas target:

Tumor-intrinsic cell death | Immune-mediated tumor/cell killing | Tumor-permissive microenvironment | MULTIPLE TARGETS

Oncology

RESEARCH AREA		MOLECULE(S)	PHASE 1	PHASE 2	PHASE 3
HEMATOLOGICAL MALIGNANCIES	**1L high-risk LBCL** (ZUMA-23)	axicabtagene ciloleucel	NCT05605899		
	R/R DLBCL	KITE-197 (next-gen CD19 CAR-T)	NCT06079164		
	R/R DLBCL	KITE-363 (CD19/20 bicistronic)	NCT04989803		
	R/R DLBCL	KITE-753 (CD19/20 bicistronic)	NCT04989803		
	2L+ high-risk FL (ZUMA-22)	axicabtagene ciloleucel	NCT05371093		
	R/R Pediatric ALL/NHL (ZUMA-4)	brexucabtagene autoleucel	NCT02625480		
	R/R MM (iMMagine-3)[a]	anitocabtagene autoleucel	NCT06413498		
	R/R MM (iMMagine-1)[a]	anitocabtagene autoleucel	NCT05396885		
	R/R MM (Phase 1)[a]	anitocabtagene autoleucel	NCT04155749		
BREAST	**1L mTNBC, PD-L1-** (ASCENT-03)	sacituzumab govitecan (SG)	NCT05382299		*Primary readout complete*
	1L mTNBC, PD-L1+ (ASCENT-04)[b]	sacituzumab govitecan + pembro	NCT05382286		*Primary readout complete*
	Adjuvant TNBC (ASCENT-05)[c]	sacituzumab govitecan + pembro	NCT05633654		
	HR+/HER2- chemo-naïve mBC (ASCENT-07)	sacituzumab govitecan	NCT05840211		
THORACIC	**1L mNSCLC, PD-L1 TPS≥50%** (EVOKE-03)[b]	sacituzumab govitecan + pembro	NCT05609968		
	2L ES-SCLC (EVOKE-SCLC-04)	sacituzumab govitecan	NCT05502237		
	1L mNSCLC, regardless of PD-L1 expression status (STAR-121)[d]	domvanalimab + zimberelimab + chemo	NCT05186974		
	1L mNSCLC (EVOKE-02)[b]	sacituzumab govitecan + pembro ± chemo	NCT04262856		
	Stage 2-3 resectable NSCLC, 1-2L mNSCLC (VELOCITY-Lung)[d,e]	zim ± dom ± etruma ± chemo/SG combinations	NCT05633667		
	1L/2L+ mNSCLC (EDGE-Lung)[d]	zim ± dom ± quemli ± chemo combinations	NCT06801834		
	1L r/m HNSCC, regardless of PD-L1 expression status (VELOCITY-HNSCC)[d]	zimberelimab + chemotherapy ± domvanalimab	NCT06727565		
GU	**1L/2L+ mUC** (TROPHY U-01, multicohort)	sacituzumab govitecan + combinations	NCT03547973		
GYN	**2L+ mEC** (ASCENT-GYN-01)[f]	sacituzumab govitecan	NCT06486441		
OTHER SOLID TUMORS	**Solid tumors** (EVER-132-003)	sacituzumab govitecan	NCT05119907		
	Solid tumor basket study (TROPiCS-03)[g]	sacituzumab govitecan	NCT03964727		
	Solid tumors	denikitug (CCR8) ± zim	NCT05007782		
	Solid tumors	GS-4528 (IL-2 variant) ± zim	NCT05840224		
	Solid tumors	GS-0201 (PARP1) ± SG	NCT06167317		
	Solid tumors	GS-2121 (undisclosed MoA) ± zim	NCT06532565		
	Solid tumors[h]	GS-0321 (IL18BP) ± zim	NCT06759649		
	Solid tumors	GS-5319 (undisclosed MoA)	NCT07128303		
	Solid tumors[i]	XTX301 (IL-12)	NCT05684965		
	Glioblastoma[j]	EGFR IL13Ra2 CAR-T	NCT05168423		
	Neuroblastoma[k]	GPC2 CAR-T	NCT05650749		
	Hepatocellular carcinoma	GPC3 Armored CAR-T	Planned		

Non-oncology

AD	**Multiple indications**	KITE-363 (CD19/20 bicistronic)	Preclinical		

Optionable Partner Programs[l]

Arcus: 2 clinical stage programs: Advanced Cancers

MacroGenics: 1 clinical stage program: Advanced cancers

Targets

GS-0201	SG	GS-5319	Anito-cel	Axi-cel, Brexu-cel	KITE-197	KITE-363, KITE-753	GS-9911	GS-4528	XTX301	Zim	Dom	EGFR IL13Ra2 CAR-T	GPC2 CAR-T	GPC3 Armored CAR-T	Etruma	Quemli	Denikitug	GS-2121	GS-0321
PARP1	**Trop-2**	**undisclosed MOA**	**BCMA**	**CD19**	**CD19 Next-gen CAR-T**	**CD19/20 bicistronic**	**DGKα**	**IL-2 variant**	**IL-12**	**PD-1**	**TIGIT**	**EGFR IL13Ra2**	**GPC2**	**GPC3**	**$A_{2A}R/A_{2B}R$**	**CD73**	**CCR8**	**undisclosed MoA**	**IL18BP**

[a]In collaboration with Arcellx, Inc. [b]In collaboration with Merck Sharp & Dohme. [c]In collaboration with Alliance Foundation Trials, LLC and National Surgical Adjuvant Breast and Bowel Project Foundation, Inc. [d]In collaboration with Arcus Biosciences. [e]Gilead has returned its license to etrumadenant to Arcus. [f]In collaboration with the Gynecologic Oncology Group (GOG) Foundation, the European Network of Gynaecological Oncological Trial Groups (ENGOT) and the Asia-Pacific Gynecologic Oncology Trials Group (APGOT). [g]TROPiCS-03: mNSCLC, mSCLC, mHNSCC, mEC. [h]Operationalized by Compugen. Also referred to as COM503. [i]Operationalized by Xilio Development, Inc. [j]In collaboration with University of Pennsylvania. [k]In collaboration with Children's Hospital of Philadelphia. [l]Optionable Partner Programs: Selected programs listed are optionable partner programs. Gilead has not opted into these programs unless otherwise noted.

1L, first line; **2L**, second line; **$A_{2A}R/A_{2B}R$**, adenosine 2A receptor/adenosine 2B receptor; **AD**, autoimmune diseases; **ALL**, acute lymphoblastic leukemia; **BC**, breast cancer; **BCMA**, B-cell maturation antigen; **CAPOX**, capecitabine + oxaliplatin; **CAR**, chimeric antigen receptor; **CCR8**, chemokine receptor 8; **CD19/20**, cluster of differentiation 19/20; **Chemo**, chemotherapy; **DLBCL**, diffuse large B-cell lymphoma; **dom**, domvanalimab; **EC**, endometrial cancer; **EGFR**, epidermal growth factor receptor; **ES-SCLC**, extensive-stage small cell lung cancer; **etruma**, etrumadenant; **FL**, follicular lymphoma; **FOLFOX**, FOLinic acid, Fluorouracil and OXaliplatin; gem/nab-pac, gemcitabine/ nab-paclitaxel; **GI**, gastrointestinal; **GPC2/3**, glypican 2/3; **GU**, genitourinary; **GYN**, gynecological; **HER2**, human epidermal growth factor receptor 2; **HNSCC**, head and neck squamous cell carcinoma; **HR**, hormone receptor; **IL-2/12**, interleukin-2/12; **IL13Ra2**, interleukin-13 receptor subunit alpha 2; **IL18P**, interleukin-18 binding protein; **LBCL**, large B-cell lymphoma; **m**, metastatic; **MM**, multiple myeloma; **MoA**, mechanism of action; **NCT**, national clinical trial; **NHL**, non-Hodgkin lymphoma; **nivo**, nivolumab; **NSCLC**, non-small cell lung cancer; **PARP1**, poly adenosine diphosphate (ADP) ribose polymerase 1; **PD-(L)1**, programmed cell death (ligand) 1; **pembro**, pembrolizumab; **quemli**, quemliclustat; **r/m**, recurrent/metastatic; **R/R**, relapsed/refractory; **SCLC**, small cell lung cancer; **SG**, sacituzumab govitecan; **TIGIT**, T cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains; **TNBC**, triple-negative breast cancer; **TPS**, tumour proportion score; **Trop-2**, trophoblast cell surface antigen 2; **UC**, urothelial cancer; **zim**, zimberelimab.

GILEAD and the GILEAD logo are trademarks of Gilead Sciences, Inc. KITE and the KITE logo are trademarks of Kite Pharma, Inc. All other trademarks referenced herein are the property of their respective owners. © 2026 Gilead Sciences, Inc. All rights reserved. MA-UNB-NA-US-00295 MRC Approved 02/02/2026